miRNA-222 can promote the resistance of breast cancer cells to Adriamycin chemotherapy via PTEN downregulation and the subsequent induction of Akt, leading to p27 inhibition and decreasing apoptotic cell death [191]. This evidence concerns the gene CDKN1B and breast carcinoma.